Who
Andrea Ellis
Director
Company insider
Files Form 4 as: Director, BridgeBio Pharma.
In numbers
- Trades disclosed
- 32
- Buys
- 1
- Sells
- 5
- Bought
- $101K
- Sold
- $13.5M
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 17 Aug 2021
- Last trade
- 9 Jul 2026
- Last filed
- 13 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jul 2026filed 13 Jul 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code M | $288K17,167 at $16.75 | filing |
| 9 Jul 2026filed 13 Jul 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $1.4M17,167 at $84.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,167 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,167 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code M | $288K17,167 at $16.75 | filing |
| 9 Jul 2026filed 13 Jul 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $1.4M17,167 at $84.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code A | —3,990 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,277 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,277 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code A | —3,990 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code M | $549K64,921 at $8.45 | filing |
| 4 Mar 2026filed 6 Mar 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $4.2M64,921 at $64.87 | filing |
| 4 Mar 2026filed 6 Mar 2026 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —64,921 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —64,921 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code M | $549K64,921 at $8.45 | filing |
| 4 Mar 2026filed 6 Mar 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $4.2M64,921 at $64.87 | filing |
| 5 Aug 2025filed 7 Aug 2025 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,167 at $0.00 | filing |
| 5 Aug 2025filed 7 Aug 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code M | $288K17,167 at $16.75 | filing |
| 5 Aug 2025filed 7 Aug 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $841K17,167 at $49.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,425 at $0.00 | filing |
News
BridgeBio Pharma (NASDAQ:BBIO) Given New $91.00 Price Target at CitigroupBBIO · dailypolitical.com · 19 Oct 2026
0 headlines in the last 90 days name Andrea Ellis; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.